Login / Signup

A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.

Atish D ChoudhuryKathryn P GrayJeffrey G SupkoLauren C HarshmanMary-Ellen TaplinAmanda F PaceMatthew FarinaKatherine A ZukotynskiBrandon BernardPhilip W KantoffMark PomerantzChristopher Sweeney
Published in: The Prostate (2018)
Based on tolerability and preliminary efficacy, 40 mg cabozantinib plus 1000 mg abiraterone daily is the RP2D.
Keyphrases
  • clinical trial
  • open label
  • metastatic renal cell carcinoma
  • double blind
  • squamous cell carcinoma
  • small cell lung cancer
  • phase ii
  • physical activity
  • phase iii